The mechanism the Zagreb group proposed to unify its findings, and the evidence offered for it

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
Across its models the Zagreb group reports that BPC-157 counteracts the effects of both the nitric oxide synthase inhibitor L-NAME and the precursor L-arginine, and proposes that the peptide modulates the nitric oxide system toward a protective set-point. A second strand proposes rapid recruitment of collateral blood vessels around an occlusion or injury, documented by direct observation of vessels in anaesthetised rats. Independent work has reported increased expression of the VEGF receptor 2 and activation of downstream endothelial signalling in cultured cells. Together these form the vascular hypothesis: that the peptide acts on vessels and endothelium and that tissue effects follow. It is a coherent proposal supported mainly by the group own experiments.

The nitric oxide experiments

In many of the group papers, a model is run with the peptide, with L-NAME, with L-arginine, and with combinations, and the peptide is reported to reverse the effects of both the inhibitor and the precursor. Reversing both directions of perturbation is an unusual pattern that the group interprets as stabilisation of the system and critics interpret as hard to reconcile with a single mechanism.

Direct measurement of nitric oxide or synthase activity is less common in the literature than pharmacological inference.

The vessel observations

Rats with a ligated vessel are examined for opening of alternative pathways within minutes to hours of peptide administration, and the group reports consistent recruitment. The observations are direct and visual; they have not been independently reproduced in published form. The in vitro VEGFR2 findings from other groups are consistent with an angiogenic action but are a different kind of evidence.

Angiogenesis is also a reason for caution in any context where new vessels are unwanted.

Why it is here

Because the mechanism is the frame through which the whole literature is presented, and a reader should know what it rests on. It describes a hypothesis and no use of the pack.

The BPC-157 + TB500 blend is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for each component of the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
BPC-157 + TB500 Pack5 mg + 5 mgAED 510In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

The nitric oxide experiments?

In many of the group papers, a model is run with the peptide, with L-NAME, with L-arginine, and with combinations, and the peptide is reported to reverse the effects of both the inhibitor and the precursor. Reversing both directions of perturbation is an unusual pattern that the group interprets as stabilisation of the system and critics interpret as hard to reconcile with a single mechanism.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

BPC-157 + TB500 Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.